Evidence map›Paper›PMID 41922631›Full record

ArticleCell biology and toxicology2026

ALKBH5/IGF2BP1-mediated m

Cheng Yan, Xuan Li, Ying Zhao, Jinhui Chen, Xinke Peng, Daichao Wu, Yabin Chang, Guodong Chen

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell biology and toxicology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Cheng Yan *Department of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China.
Xuan Li *Department of Vascular Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Enze Hospital, Taizhou Enze Medical Center (Group), Taizhou, Zhejiang, China.
Ying Zhao *Harbin Medical University, Heilongjiang, Harbin, China.
Jinhui ChenDepartment of Vascular Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Enze Hospital, Taizhou Enze Medical Center (Group), Taizhou, Zhejiang, China.
Xinke PengDepartment of Neurology, Second Xiangya Hospital, Central South University, Changsha, Hunan, China.
Daichao WuDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. wudaichao@usc.edu.cn.
Yabin ChangCancer Center, Dongguan Key Laboratory of Precision Diagnosis and Treatment for Tumors, The Tenth Affiliated Hospital, Southern Medical University (Dongguan People's Hospital), Dongguan, Guangdong, China. cybyyy@163.com.
Guodong ChenDepartment of Hepatopancreatobiliary Surgery, The First Affiliated Hospital, Hengyang Medical School, University of South China, Hengyang, Hunan, China. chenguodong@usc.edu.cn.

Funding

National Natural Science Foundation of China 82305403
6 · The paper itself

Abstract

backgroundThe upregulation of the ubiquitin ligase TRIM37 is associated with an adverse prognosis in pancreatic ductal adenocarcinoma (PDAC). This study investigates the mechanism and oncogenic consequence of TRIM37 upregulation in PDAC development.

methodsTRIM37 expression was assessed by qPCR and Western blotting. The effects of TRIM37 knockdown and overexpression on cell proliferation, colony formation, stemness capacity was investigated through in vitro assays, and the role in PDAC was evaluated through vivo experiments. RNA immunoprecipitation assay and Actinomycin D assay were performed to detect the mechanism of TRIM37 upregulation. The TRIM37 and RBMX interaction were determined through co-immunoprecipitation and immunofluorescence.

resultsWe identified TRIM37 as a critical oncoprotein in PDAC, and its overexpression was strongly correlated with poor prognosis. As a ubiquitin ligase, TRIM37 targets the tumor suppressor RBMX for proteasomal degradation, promoting glycolytic reprogramming and driving aggressive cancer phenotypes, including enhanced proliferation, migration, and stemness. Furthermore, we found that the ALKBH5-IGF2BP1 axis promotes TRIM37 expression by controlling N6-methyladenosine (m

conclusionsOur findings establish the ALKBH5/IGF2BP1-TRIM37-RBMX signaling axis as a pivotal driver of PDAC progression, highlighting the intersection of m

Indexed as

AlkB Homolog 5, RNA DemethylaseCarcinogenesisCarcinoma, Pancreatic DuctalGlycolysisPancreatic NeoplasmsRNA-Binding ProteinsTripartite Motif ProteinsUbiquitin-Protein LigasesAdenosineAnimalsCell Line, TumorCell MovementCell ProliferationGene Expression Regulation, NeoplasticHumansMiceAdenosineALKBH5 protein, humanAlkB Homolog 5, RNA DemethylaseN-methyladenosineRNA-Binding ProteinsTRIM37 protein, humanTripartite Motif ProteinsUbiquitin-Protein LigasesGlycolysisN6-methyladenosinePancreatic ductal adenocarcinomaRBMXTRIM37Ubiquitination

Identifiers

PMID41922631
PMCPMC13167913

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.